Floatz logo

Spedox-6

KRAS Mutation-Related Tumors

University of California, IrvineunclassifiedPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

20 Active assets in the KRAS Mutation-Related Tumors cohort.

Asset / SponsorPhaseRating
Hydroxychloroquine
Abramson Cancer Center at Penn Medicine
Phase 2B
Binimetinib
Abramson Cancer Center at Penn Medicine
Phase 2B
Irinotecan
Institut de Recherches Internationales Servier
Phase 1/2CCC
FLUOROURACILUM
Institut de Recherches Internationales Servier
Phase 1/2CCC
Calcium folinate pentahydrate
Institut de Recherches Internationales Servier
Phase 1/2CCC

View all 25 →

Same molecule, other indications

Spedox-6 is also rated in:

soft tissue sarcomaDormant
CCC
Indicative ·
48 / 100
View asset →
triple-negative breast carcinomaDormant
CC
Indicative ·
41 / 100
View asset →
cervical cancerDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →